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Koszegi S, Sparding N, Genovese F, Wagner LJ, Szabo AJ, Fekete
A. Reduced O-GlcNAcylation and tubular hypoxia contribute to the
antifibrotic effect of SGLT2 inhibitor dapagliflozin in the diabetic
kidney. Am J Physiol Renal Physiol 318: F1017–F1029, 2020. First
published March 2, 2020; doi:10.1152/ajprenal.00021.2020.—Dia-
betic kidney disease is a worldwide epidemic, and therapies are
incomplete. Clinical data suggest that improved renal outcomes by
Na-glucose cotransporter 2 inhibitor (SGLT2i) are partly beyond
their antihyperglycemic effects; however, the mechanisms are still
elusive. Here, we investigated the effect of the SGLT2i dapagliflozin
(DAPA) in the prevention of elevated O-GlcNAcylation and tubular
hypoxia as contributors of renal fibrosis. Type 1 diabetes was induced
by streptozotocin in adult male Wistar rats. After the onset of diabetes,
rats were treated for 6 wk with DAPA or DAPA combined with
losartan (LOS). The effect of hyperglycemia was tested in HK-2 cells
kept under normal or high glucose conditions. To test the effect of
hypoxia, cells were kept in 1% O2 for 2 h. Cells were treated with
DAPA or DAPA combined with LOS. DAPA slowed the loss of renal
function, mitigated renal tubular injury markers (kidney injury mol-
ecule-1 and neutrophil gelatinase-associated lipocalin), and reduced
tubulointerstitial fibrosis. DAPA diminished high glucose-induced
protein O-GlcNAcylation and moderated the tubular response to
hypoxia through the hypoxia-inducible factor pathway. DAPA alone
was as effective as combined treatment with LOS in all outcome
parameters. These data highlight the role of ameliorated O-GlcNAcy-
lation and diminished tubular hypoxia as important benefits of
SGLT2i treatment. Our results support the link between glucose
toxicity, tubular hypoxia, and fibrosis, a vicious trio that could be
targeted by SGLT2i in kidney diseases of other origins as well.
diabetes; kidney fibrosis; O-GlcNAcylation; Na-glucose cotrans-
porter 2 inhibitors; tubular hypoxia
INTRODUCTION
Diabetic kidney disease (DKD) develops in 20–30% of
patients with diabetes and is the leading cause of end-stage
renal disease in adults (14). Impaired renal function and dia-
betic structural lesions such as glomerulosclerosis, tubulointer-
stitial fibrosis, and endothelial injury are the result of a com-
plex process of constant hyperglycemia, activated renin-angio-
tensin-aldosterone system (RAAS), and various other factors.
Current guidelines recommend RAAS inhibitors (RAASi) as
the main therapy of DKD (33). However, RAASi merely
ameliorate renal impairment but cannot prevent DKD progres-
sion either in experimental studies or in large clinical DKD
cohorts (18, 37, 38). Thus, novel therapies and early interven-
tion directly targeting the diabetic kidney are of paramount
importance.
Na-glucose cotransporter 2 inhibitors (SGLT2i) have re-
cently been approved as new-generation antidiabetics with a
unique mechanism of action. SGLT2i act by inhibiting glucose
reabsorption in renal proximal tubules, thereby lowering
plasma glucose levels in an insulin-independent manner (49).
SGLT2i have been routinely used in type 2 diabetes mellitus
(T2DM) for years, but only dapagliflozin (DAPA) and sotagli-
flozin have been approved in type 1 diabetes mellitus (T1DM)
to date (2). Multicenter clinical trials (EMPA-REG, CANVAS,
and DAPA-TIMI 58) have indicated that SGLT2i considerably
hinder the progression of DKD (42, 43, 53). Comparison
studies have suggested that SGLT2i are more renoprotective
than other antidiabetics (e.g., glucagon-like peptide analogs)
with similar glucose-lowering effects (59). These results were
substantiated by another study in which reduced albuminuria
was independent of changes in HbA1c, blood pressure, or body
weight in DAPA-treated patients with T2DM (21). Thus,
renoprotection may arise not only because of lower glucose
levels but because of other mechanisms of SGLT2i, such as
inhibition of tubuloglomerular feedback, anti-inflammatory ef-
fects, or antifibrotic effects.
We have previously shown that RAASi prevent the progres-
sion of hyperglycemia-induced fibrotic processes via directly
inhibiting extracellular matrix (ECM) production of renal fi-
broblasts independent of their vasoactive effect (30). Further-
more, we demonstrated that RAASi diminish elevated protein
O-GlcNAcylation in the kidneys of T1DM rats (12). O-Gl-
cNAcylation is a posttranslational modification regulating pro-
tein function in many cellular processes (e.g., signaling, tran-
scription, and cytoskeletal functions), and chronic upregulation
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of O-linked N-acetylglucosamine (O-GlcNAc) is a known
contributor to glucose toxicity in diabetes. In parallel, others
have shown that increased O-GlcNAcylation enhances profi-
brotic signaling in mesangial cells exposed to high glucose
(15). These results suggest that this posttranslational modifi-
cation is a potential key factor in diabetes-related fibrotic
processes.
Elevated tubular oxygen demand causes hypoxia, which is
another important and early event in the development of DKD
and is a major driver of disease progression (46). The chronic
hypoxia hypothesis was the first to suggest that chronic oxygen
deprivation might be responsible for tubulointerstitial fibrosis
(11). This hypothesis has since been robustly confirmed in both
animal and human studies (47), revealing that chronic tubulo-
interstitial hypoxia as a final common pathway leading to
end-stage renal disease. The identification of molecular mech-
anisms involved in hypoxia-driven renal fibrosis remains a task
awaiting to be completed.
Considering the importance of SGLT2i as novel antidiabet-
ics, it is crucial to characterize their renoprotective mecha-
nisms, especially in light of data suggesting that the beneficial
effects of DAPA are beyond its blood glucose-lowering prop-
erties. The aim of the present study was to investigate the
potential antifibrotic effects of DAPA in a streptozotocin
(STZ)-induced T1DM and subsequent DKD model with spe-
cial focus on protein O-GlcNAcylation and tubular hypoxia,
both major processes leading to renal fibrosis.
METHODS
Study approval. All animal procedures were approved by the
Committee on the Care and Use of Laboratory Animals of Semmel-
weis University (Budapest, Hungary) (PEI/001/1731-9-2015). The
investigators state their confirmation of compliance to understand the
ethical principles under which the American Journal of Physiology
operates and that our work complies with its animal ethics checklist.
Materials. All chemicals and reagents were purchased from Sigma-
Aldrich (St. Louis, MO), and all standard plastic laboratory equipment
was purchased from Sarstedt (Numbrecht, Germany) unless otherwise
stated.
Animals. Experiments were performed on 6-wk-old male Wistar
rats (Rattus norvegicus) purchased from Toxi-Coop (Budapest, Hun-
gary). Rats were housed in groups of three under a 12:12-h light-dark
cycle at 22  2°C with free access to standard rodent diet and tap
water.
Induction of diabetes and experimental design. Diabetes mellitus
was chemically induced by a single intraperitoneal injection of 65
mg/kg body wt STZ in 0.1 M citrate buffer (pH 4.5). The blood
glucose level was measured three times from the tail vein with a
Dcont Ideal device (77 Elektronika, Budapest, Hungary). Animals
with a peripheral blood glucose value above 15 mmol/L 72 h after the
STZ injection were enrolled in the study. Diabetic rats were randomly
divided into three groups [n  6 in the diabetes group and n  7 in
treatment groups] and were treated per os as follows: 1) isotonic saline
(154 mmol/L NaCl) as vehicle (D group), 2) dapagliflozin dissolved
in isotonic saline (D  DAPA group; 1 mg·kg body wt1·day1 for
6 wk), and 3) DAPA  losartan (LOS) dissolved in isotonic saline
(D  DAPA  LOS group; 1 mg body wt1·day1 DAPA for 6 wk 
20 mg body wt1·day1 LOS in the last 3 wk of the protocol). The
applied angiotensin type 1 receptor blocker dose was adopted from
our previous studies in line with literary data where effective blockade
of the angiotensin II type 1 receptor was achieved without changes in
systemic blood pressure (4, 8). The dose of DAPA was adopted from
the literature, and the standard dose conversion between animals and
humans was used (19, 35). Age-matched controls (n  6) received
the equivalent volume of citrate buffer without STZ one time and the
same amount of saline by oral gavage daily at the same time as the
diabetic animals during the 6-wk study period. Rats were weighed
daily; blood glucose levels were measured weekly. Blood pressure,
serum, and urinary parameters were determined two times throughout
the study period. At the end of the protocol, rats were euthanized by
a mixture of 75 mg/kg body wt ketamine (Richter Gedeon, Budapest,
Hungary) and 10 mg/kg body wt xylazine (Medicus Partner, Biator-
bagy, Hungary). Blood, urine, and kidney samples were collected and
stored for further investigations.
Measurement of arterial blood pressure and metabolic and renal
parameters. Systolic and diastolic pressures were measured on the tail
vein using a CODA Standard monitor system (EMKA Technologies,
Paris, France), which uses clinically validated proprietary volume
pressure recording. Mean arterial pressure (MAP) was calculated.
Recording was performed under standardized conditions in a quiet
and comfortable environment with no distractions. Rats were accli-
mated to the system for 10 min/day for 2 days before the measure-
ments were started. Following acclimation, rats remained calm and
still in the holder on the day of testing. Serum and urinary parameters
were photometrically determined with commercially available kits on
a Hitachi 912 photometric chemistry analyzer (Roche Hitachi, Basel,
Switzerland). Creatinine clearance, protein excretion, and glucosuria
were determined from 24-h collected urine. Urinary kidney injury
molecule-1 (KIM-1) and neutrophil gelatinase-associated lipocalin
(NGAL) levels were measured using ELISA (R&D Systems, Minne-
apolis, MI).
Cell culture and treatment. Human proximal tubular epithelial cell
line (HK-2 cells; LGC Standards, catalog no. CRL-2190, American
Type Culture Collection, Manassas, VA) was grown in DMEM
supplemented with 10% FBS, 1% L-glutamine, and 1% antibiotic-
antimycotic solution containing 10,000 IU/mL penicillin, 10 mg/mL
streptomycin, and 25 mg/mL amphotericin B (ThermoFisher Scien-
tific, Waltham, MA). Cells were incubated at 37°C in a humidified
atmosphere of 5% CO2 and 95% air. Before treatments, cell viability
was determined by methylthiazoletetrazolium (MTT) assay (Roche
Diagnostics, Indianapolis, IN) and also assessed by trypan blue
exclusion. Next, cells were plated either in six-well plates (5  105
cells/well) or in 24-well plates (1.2  105 cells/well), and there was a
growth arrest period of 24 h in serum-free medium before treatment in
all experiments. The nontoxic dosages of DAPA and LOS were
confirmed by MTT assay.
Two set of experiments were performed. In the hyperglycemic
model, the effect of high glucose was tested; therefore, proximal
tubular cells were kept under normal glucose (5.5 mM) conditions and
treated with high mannitol (35 mM) or high glucose (35 mM) for 24
h. High glucose-treated cells were treated with 10 M DAPA or 10
M DAPA combined with 10 M LOS. Cells in normal glucose
conditions served as controls, and mannitol-treated cells were used for
testing hyperosmolarity. In the hypoxia model, hypoxia was induced
in a bold line stage top CO2/O2 incubator (Okolab, Ottaviano, Italy)
by keeping the cells in 1% O2 for 2 h. Cells cultured in 25 mM glucose
medium were treated as follows: 10 M DAPA or 10 M DAPA
combined with 10 M LOS (24 h before harvest). Cells were
harvested at the end of hypoxia. Cells cultured under normoxic
conditions served as controls.
Renal histology. The renal cortex was separated under a light
microscope, fixed immediately in 4% paraformaldehyde, and embed-
ded in paraffin, and 5-m-thick sections were cut. Mesangial matrix
expansion was evaluated on periodic acid-Schiff-stained sections,
interstitial fibrosis was evaluated on Masson’s trichrome-stained sec-
tions, and collagen accumulation was evaluated on picrosirius red-
stained kidney sections. Histological evaluation was performed as
previously described (30) in a double-blinded fashion using Pan-
oramic Viewer 1.15.2 software (3D HISTECH, Budapest, Hungary).
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Immunohistochemistry. All reagents for O-GlcNAc and fibronectin
immunohistochemistry were obtained from Hisztopatologia (Pecs,
Hungary). Slides were deparaffinized in xylene, rehydrated in graded
ethanol series, and washed in distilled H2O. Heat-induced epitope
retrieval was performed by boiling the paraffin-embedded tissue
sections in citrate buffer (pH 6). Slides were peroxidase blocked, and
nonspecific attachments were inhibited with protein solution. Sections
were incubated against fibronectin (catalog no. ab2413, Abcam, Cam-
bridge, MA) or O-GlcNAc (shown in Table 1) antibodies followed by
peroxidase-labeled anti-rabbit antibody. Fibronectin was visualized
with the HISTOLS-Resistant AEC Chromogen/Substrate System
counterstained with hematoxylin and eosin and mounted with perma-
nent mounting medium. Evaluation of fibronectin staining was per-
formed similarly to PAS-stained samples.
Immunocytochemistry. HK-2 cells were cultured in tissue culture
chambers, and various treatments or hypoxia were applied. Next, cells
were fixed in 4% paraformaldehyde, washed, and permeabilized with
Triton X-100. After being blocked (5% BSA), cells were incubated
with the same O-GlcNAc and hypoxia-inducible factor-1 (HIF-1)
antibodies used for Western blot analysis followed by specific sec-
ondary antibody Alexa Fluor 488 goat anti-mouse (catalog no.
A-11001, Invitrogen, Carlsbad, CA) and Alexa Fluor 488 chicken
anti-rabbit (catalog no. A-21441, Invitrogen), respectively. Samples
were counterstained with Hoechst 33342 (catalog no. 4082S, RRID:
AB_10626776, Cell Signaling Technology, Danvers, MA). Appropri-
ate controls were performed, omitting the primary antibody to assure
the specificity. Cells were imaged using an inverted microscope (Ti2,
Nikon, Tokyo, Japan) equipped with a 20 objective (numerial
aperture 0.75, CFI Plan Apochromat Lambda). For the semiquantita-
tive evaluation of fluorescence, 10 visual fields/treatment were ana-
lyzed with ImageJ software (RRID:SCR_003070, National Institutes
of Health, Bethesda, MD; see Ref. 44).
Biomarkers of ECM formation and degradation. Biomarkers
[rPRO-C3, measuring collagen type III formation, uC3M, measuring
collagen type III degradation by matrix metalloproteinase (MMP)-9,
and TUM, measuring tumstatin, a collagen type IV fragment degraded
by MMP-9] were measured in rat urine samples as we have previously
described (30). Biomarker levels were normalized by levels of urinary
creatinine measured using the QuantiChrom Creatinine Assay kit
(BioAssay Systems).
Quantitative RT-PCR. Total RNA was extracted using the Total
RNA Mini Kit (Geneaid Biotech, New Taipei City, Taiwan). RNA
(500 ng) was reverse transcribed using the Maxima First Strand
cDNA Synthesis Kit for quantitative RT-PCR (ThermoFisher Scien-
tific) to generate first-strand cDNA. mRNA expressions of transform-
ing growth factor-	1 (Tgfb1 and TGFB1), connective tissue growth
factor (Ctgf and CTGF), platelet-derived growth factor-B (Pdgfb and
PDGFB), fibronectin 1 (Fn1), 18S ribosomal RNA (Rn18s and
RN18S), HIF1A, and GAPDH were determined in duplicate using
LightCycler 480 SYBR Green I Master enzyme mix (Roche Diag-
nostics, Indianapolis, IN) and specific primers (Table 2). Results were
analyzed by LightCycle 480 software (version 1.5.0.39, Roche Diag-
nostics). Target gene expressions were normalized against Rn18S,
RN18S, or GAPDH housekeeping genes.
Western blot analysis. All reagents for Western blot analysis were
obtained from Bio-Rad Laboratories (Hercules, CA). Total protein
was extracted from the kidney cortex and HK-2 cells. Protein con-
centration measurement was performed with a detergent-compatible
protein assay kit. Samples were electrophoretically resolved on poly-
acrylamide gradient (4–20%) gels and transferred to nitrocellulose
membranes that were immunoblotted with specific primary antibod-
ies. The secondary antibody was horseradish peroxidase-conjugated
for chemiluminescence detection by Luminata Forte (Millipore, Bil-
lerica, MA). Details of antibodies are shown in Tables 1 and 3.
Densitometric analysis of bands was performed by Quantity One
Analysis software (RRID:SCR_01428, Bio-Rad Laboratories). After
background subtraction, integrated optical densities of bands of inter-
est were factored for Ponceau S staining to correct for variations in
total protein loading. Each blot was normalized to an internal control
so that bands on separate blots could be compared.
Statistical analysis. Data are expressed as means  SD. Statistical
analysis was performed using Prism software (version 7.0, GraphPad
Software, San Diego, CA). Multiple comparisons and interactions
were evaluated by one-way ANOVA followed by the Holm-Sidak
post hoc test. For nonparametrical data, the Kruskal-Wallis ANOVA
on ranks followed by with Dunn correction was used. P values of

0.05 were considered significant.
RESULTS
DAPA improves metabolic parameters in T1DM rats. As
expected, DAPA improved typical metabolic features of STZ-
induced T1DM, such as impaired weight gain, high levels of
blood glucose, fructosamine, and serum lipids. The blood
Table 1. List of primary antibodies and their use for Western blots
Target Protein Manufacturer Catalog No. Source Dilution Buffer Dilution
-SMA Sigma-Aldrich (St. Louis, MO) A2547 Mouse monoclonal 1% (wt/vol) nonfat milk, 1 TBS, 0.4%
(wt/vol) Tween 20
1:500
CTGF Santa Cruz Biotechnology
(Santa Cruz, CA)
SC-14939 Goat polyclonal 5% (wt/vol) nonfat milk, 1 TBS, 0.1%
(wt/vol) Tween 20
1:500
EPO Santa Cruz Biotechnology SC-5290 Mouse monoclonal 5% (wt/vol) nonfat milk, 1 TBS, 0.1%
(wt/vol) Tween 20
1:500





14711–1-AP Rabbit polyclonal 5% (wt/vol) nonfat milk, 1 TBS, 0.1%
(wt/vol) Tween 20
1:1,000
O-GlcNAc Sigma-Aldrich 07764 Rabbit polyclonal 1% wt/vol BSA, 1 TBS, 0.05% wt/vol
Tween 20
1:1,000
OGT Sigma-Aldrich O6264 Rabbit polyclonal 1% (wt/vol) nonfat milk, 1 TBS, 0.4%
(wt/vol) Tween 20
1:1,000
PDGF Santa Cruz Biotechnology SC-7878 Rabbit polyclonal 5% (wt/vol) nonfat milk, 1 TBS, 0.1%
(wt/vol) Tween 20
1:500
VEGF-A Abcam ab46154 Rabbit polyclonal 5% (wt/vol) BSA, 1 TBS, 0.1%
(wt/vol) Tween 20
1:1,000
-SMA; -smooth muscle actin; CTGF, connective tissue growth factor; EPO, erythropoietin; HIF-1, hypoxia-inducible factor-1; OGA, O-GlcNAcase;
O-GlcNAc, O-linked N-acetylglucosamine; OGT, O-GlcNAc transferase; PDGF, platelet-derived growth factor; VEGF-A, vascular endothelial growth factor-A;
TBS, Tris-buffered saline.
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glucose level was decreased in the first wk, reaching a decline
of 41% by the second wk. By the end of the experiment, the
blood glucose level was 47% lower in DAPA versus the
diabetic group. Hemoglobin levels were lower in diabetic rats,
but DAPA restored it to control levels (Table 4). Combination
therapy with LOS did not result in synergistic effect.
DAPA slows the progression of diabetes-induced renal func-
tional and structural impairment. The development of DKD
was confirmed by the decline of renal function. DAPA mark-
edly improved creatinine clearance, serum creatinine, blood
urea nitrogen, and proteinuria (Fig. 1, A–D). Urinary excretion
of KIM-1 and NGAL was elevated in the diabetic group versus
controls, whereas DAPA decreased their levels by 50%,
indicating milder tubular damage (Fig. 1, E and F). Further-
more, creatinine clearance correlated with urinary KIM-1
(R2  0.202, P  0.0252) or urinary NGAL (R2  0.546, P 
0.0001) (Fig. 1, G and H). The blood glucose level and
proteinuria also correlated with urinary KIM-1 and NGAL
(data not shown).
Histological changes were consistent with functional deteri-
oration. Evaluation of PAS-stained sections revealed massive
hypertrophy, mesangial matrix expansion, and basal membrane
thickening in the glomeruli of diabetic rat kidneys. DAPA
minimized mesangial matrix expansion and ameliorated struc-
tural damage as reflected by smaller PAS-positive glomerular
areas (Fig. 1I). Additional LOS treatment did not result in a
synergistic effect in any of the observed parameters.
Renal fibrogenesis is alleviated by DAPA. Novel urinary
biomarkers of ECM remodeling showed increased collagen
type III formation (rPRO-C3) and increased MMP-9-mediated
degradation of collagen type III (uC3M) and collagen type IV
(TUM) in diabetic rats. DAPA treatment decreased rPRO-C3
and TUM levels, whereas the uC3M level remained unchanged
(Fig. 2, A–C).
Renal Tgfb1, Pdgfb, and Ctgf mRNA expressions were
upregulated in diabetic rats. DAPA decreased Pdgfb and Ctgf
to control levels, while surprisingly it had no effect on Tgfb1
expression (Fig. 2, D–F).
Extensive tubulointerstitial fibrosis was observed on Mas-
son’s trichrome-stained sections of diabetic kidneys. DAPA
reduced the amount of renal fibrotic tissue (Fig. 2G), whereas
the combination with LOS had no synergistic effect in any of
the observed parameters.
A positive correlation was found between tubulointerstitial
fibrosis (evaluated on Masson’s trichrome-stained sections)
and rPRO-C3 (R2  0.4459, P  0.0003), uC3M (R2 
0.1922, P  0.0364), and TUM (R2  0.2285, P  0.0182),
which strengthens the relevance of these parameters as novel
urinary biomarkers of renal fibrosis (Fig. 2, H–J). Furthermore,
suggesting that DAPA prevents fibrogenesis, the increased
renal protein level of the specific myofibroblast marker
-smooth muscle actin (-SMA) in diabetic rats was also
mitigated by DAPA as well (Fig. 2K).
DAPA prevents renal collagen and fibronectin accumulation.
Collagens and the adhesive glycoprotein fibronectin are the
most common matrix components in kidney fibrosis. To
assess accumulation of collagen components, picrosirius red
staining was performed. Weak collagen staining was de-
Table 3. List of secondary antibodies used for Western blots
Target Protein Manufacturer Catalog No. Source Dilution Buffer Dilution
Goat IgG Santa Cruz Biotechnology (Santa Cruz, CA) 2020 Donkey 1 Tris-buffered saline, 0.05% (wt/vol) Tween 20 1:3,000
Mouse IgG Cell Signaling Technology (Danvers, MA) 7076 Goat
Rabbit IgG Cell Signaling Technology 7074 Goat
Table 2. Sequences of primer pairs for quantitative RT-PCR
Gene National Center for Biotechnology Information Ref. No. Primer Pairs Product Length, bp
Tgfb1 NM_021578.2 Forward: 5=-GCACCGGAGAGCCCTGGATACC-3=
Reverse: 5=-CCCGGGTTGTGTTGGTTGTAGAGG-3=
222
Ctgf NM_022266.2 Forward: 5=-TCCACCCGGGTTACCAATGACAATAC-3=
Reverse: 5=-CTTAGCCCGGTAGGTCTTCACACTGG-3=
195
Pdgfb NM_031524.1 Forward: 5=-TCGATCGCACCAATGCCAACTTCC-3=
Reverse: 5=-CACGGGCCGAGGGGTCACTACTGT-3=
236
Fn1 NM_019143.2 Forward: 5=-GGGCCGGGGCAGATGGAAATG-3=
Reverse: 5=-CCCAATGCCACGGCCCTAACAGTA-3=
142
Rn18s NR_046237.1 Forward: 5=-GCGGTCGGCGTCCCCCAACTTCTT-3=
Reverse: 5=-GCGCGTGCAGCCCCGGACATCTA-3=
105
RN18S NR_003286.4 Forward: 5=-GGCGGCGACGACCCATTC-3=
Reverse: 5=-TGGATGTGGTAGCCGTTTCTCAGG-3=
136
HIF1A NG_029606.1 Forward: 5=-CATAAAGTCTGCAACATGGAAGGT-3=
Reverse: 5=-ATTTGATGGGTGAGGAATGGGTT3=
148
TGFB1 NG_013364.1 Forward: 5=-CGAGGCGCCCGGGTTATGC-3=
Reverse: 5=-GCGTGCGGCAGCTGTACATTGACT-3=
174
CTGF NG_016131.1 Forward: 5=-CTCCACCCGGGTTACCAATGACAA-3=
Reverse: 5=-CAGCATCGGCCGTCGCTACATACT-3=
228
PDGFB NG_012111.1 Forward: 5=-GCGCCGGGAGATCTCGAACACCT-3=
Reverse: 5=-AGATGGGGCCGAGTTGGACCTGAA-3=
163
GAPDH NG_007073.2 Forward: 5=-AGCAATGCCTCCTGCACCACCAA-3=
Reverse: 5=-GCGGCCATCACGCCACAGTTT-3=
159
Tgfb1 and TGFB1, transforming growth factor-	1; Ctgf and CTGF, connective tissue growth factor; Pdgfb and PDGFB, platelet-derived growth factor subunit
B; Fn1, fibronectin 1; Rn18s and RN18S, 18S ribosomal RNA; HIF1A, hypoxia-inducible factor-1.
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tected in glomeruli and around blood vessels in control
kidneys. Extensive fibrotic tissue accumulation was ob-
served in diabetic kidneys, as shown by collagen deposition
in the interstitium. DM-induced collagen deposition was
lower in the DAPA group compared with the diabetic group,
whereas DAPA  LOS treatment had no further effect (Fig.
3, A and C). Considerable fibronectin-positive staining was
detected in the glomeruli and to a lesser extent in the
tubulointerstitium of diabetic kidneys, which was attenuated
by both treatments (Fig. 3, B and D). In parallel with
histology, renal fibronectin gene expression decreased by
50% in DAPA-treated rats (Fig. 3E). The DAPA  LOS
combination had no additional effect on the decrement of
fibronectin accumulation.
Table 4. DAPA treatment (6 wk) ameliorates type 1 diabetes mellitus-induced metabolic changes
Metabolic Parameters Control Group D Group D  DAPA Group D  DAPA  LOS Group
Body weight, g 434  37.9 256  26.7† 333  39.2†§ 312  37.8†§
Nonfasting blood glucose, mmol/L 6.52  0.57 33.0  1.12† 17.7  5.63†§ 18.1  6.16†§
Fructosamine, mol/L 142  4.12 274  13.6† 206  34.2†§ 217  27.8†§
Total cholesterol, mmol/L 1.98  0.14 2.69  0.41† 1.96  0.36§ 2.26  0.34‡
Triglycerides, mmol/L 1.39  0.58 2.84  1.26† 1.08  0.58§ 0.91  0.20§
LDL-cholesterol, mmol/L 0.44  0.15 0.84  0.12† 0.51  0.14§ 0.77  0.13†
Serum glutamate-oxaloacetate transaminase, U/L 127  17.5 347  170† 191  25.4‡ 214  88.6‡
Serum glutamate-pyruvate transaminase, U/L 42.8  7.54 166  82.2† 84.6  16.3§ 65.2  10.8§
Hemoglobin, g/L 155  16.0 88.3  9.50† 149  9.45§ 153  8.08§
Glucosuria, mmol/L UN 346  47.1† 479  91.8†‡ 401  105†
Values are means  SD. Metabolic parameters of control, diabetic (D), dapagliflozin (D  DAPA)-, or DAPA  losartan (D  DAPA  LOS)-treated
diabetic rats at the end of the 6-wk experimental period are shown. Data were analyzed by one-way ANOVA with a Holm-Sidak multiple-comparisons test (n 
6 in control and D groups and n  7 in treatment groups). †P 
 0.01 vs. control, ‡P 
 0.05 vs. diabetic, §P 
 0.01 vs. diabetic.
Fig. 1. Dapagliflozin (DAPA) treatment slows the progression of diabetes-induced renal damage. A–D: creatinine clearance, serum creatinine, blood urea nitrogen
(BUN), and protein excretion of control, diabetic (D), dapagliflozin (D  DAPA)-, and DAPA  losartan (D  DAPA  LOS)-treated diabetic rats. E and F:
excretion rates of kidney injury molecule-1 (KIM-1) and neutrophil gelatinase-associated lipocalin (NGAL). G and H: scatterplot illustrating the correlation
between creatinine clearance and KIM-1 or NGAL, respectively. I: the mesangial area was determined by the assessment of periodic acid-Schiff (PAS)-positive
and nucleus-free areas in the mesangium. Original magnification: 400. Scale bar  50 m. Mesangial fractional volume values (Vv) were defined by the ratio
of the PAS-stained mesangial area to glomerular tuft area. Bars indicate means  SD, and data were analyzed by one-way ANOVA with a Holm-Sidak
multiple-comparisons test (n  6 in control and diabetic and n  7 in treatment groups). *P 
 0.05 vs. the control group; **P 
 0.01 vs. the control group;
§P 
 0.05 vs. the diabetic group; §§P 
 0.01 vs. the diabetic group.
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DAPA diminishes elevated protein O-GlcNAcylation in the
kidney. O-GlcNAcylation is a crucial mechanism regulating
protein function in many cellular processes, and chronic
upregulation of O-GlcNAc is a known contributor to glu-
cose toxicity in diabetes (5, 20). O-GlcNAc transferase
(OGT) is responsible for adding a single O-GlcNAc to
proteins (56), whereas O-GlcNAcase (OGA) removes the
moiety.
Increased protein O-GlcNAcylation, nuclear/cytoplasmic
OGT (ncOGT), and short OGT (sOGT) protein levels were
detected in diabetic kidneys. DAPA and DAPA  LOS treat-
ment inhibited protein O-GlcNAcylation via decreased ncOGT
and sOGT protein levels (Fig. 4, A–C). Similar changes can be
observed in the representative O-GlcNAc-stained images (Fig.
4E). The long isoform of OGA (OGA-L), which is responsible
for removing O-GlcNAc residues from previously modified
proteins, remained unchanged (Fig. 4D).
Hyperglycemia-induced O-GlcNAcylation and profibrotic
marker levels are decreased by DAPA in proximal tubular
cells. The direct effects of DAPA on O-GlcNAcylation were
investigated in HK-2 cultured under hyperglycemic condi-
tions. Both Western blot and immunocytochemistry mea-
surements revealed that protein O-GlcNAcylation was in-
duced after 24 h of high glucose treatment (Fig. 5, A–E). In
Fig. 2. Fibrotic processes and tubulointerstitial fibrosis are reduced by dapagliflozin (DAPA). A–C: levels of NOOH-terminal pro-peptide of collagen type III
[collagen III formation (rPRO-C3)], collagen type III degradation fragment [matrix metalloproteinase-9-mediated degradation of type III (uC3M)], and collagen
type IV degradation fragment tumstatin [collagen type IV (TUM)] were measured in rat urine. D–F: mRNA expression of the renal profibrotic factors
transforming growth factor-	1 (Tgfb1), platelet-derived growth factor subunit B (Pdgfb), and connective tissue growth factor (Ctgf) were normalized to
housekeeping 18S ribosomal RNA (Rn18S) mRNA expression. G: representative Masson=s trichrome-stained kidney sections. Original magnification: 200.
Scale bar  200 m. Shown is the quantitative evaluation of renal tubulointerstitial fibrosis by Masson-positive and glomerulus-free versus total areas in the
kidney cortex. H–J: scatterplot illustrating the correlation between Masson’s trichrome evaluation and rPRO-C3, uC3M, or TUM. K: protein levels of -smooth
muscle actin (-SMA) were normalized to Ponceau S total protein staining as a loading control. Bars indicate means  SD, and data were analyzed by one-way
ANOVA with a Holm-Sidak multiple-comparisons test (n  6 in control and diabetic groups and n  7 in treatment groups). *P 
 0.05 vs. the control group;
**P 
 0.01 vs. the control group; §P 
 0.05 vs. the diabetic group; §§P 
 0.01 vs. the diabetic group.
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parallel, levels of the enzyme responsible for adding O-
GlcNAc moiety (ncOGT and sOGT) were higher in high
glucose-treated cells (Fig. 5, B and C). DAPA prevented
high glucose-induced protein O-GlcNAcylation and ncOGT
and sOGT upregulation in proximal tubular cells. OGA-L,
which is responsible for removing O-GlcNAc residues, was
not changed in any of the groups (Fig. 5D). The changes
were not detected in mannitol-treated cells, confirming that
the observed phenomenon is rather a consequence of hyper-
glycemia than of hyperosmolarity.
Profibrotic growth factors (TGFB1, PDFGB, and CTGF)
were increased under high glucose conditions, and DAPA
decreased the level of CTGF, whereas the levels of TGFB1 and
PDGFB remained unchanged. Similarly to in vivo experi-
ments, LOS treatment had no synergistic effect in vitro either
(Fig. 5, F–H).
DAPA moderates the tubular response to hypoxia. A hy-
poxic chamber (1% O2 for 2 h) was used to investigate the
effect of DAPA independent of its antihyperglycemic property.
Hypoxic injury was confirmed by increased HIF-1 mRNA
expression and protein levels detected by both Western blot
and immunofluorescence analyses (Fig. 6, A–E). DAPA sus-
pended HIF-1 elevation, indicating a milder hypoxic injury.
Moreover, the treatment prevented HIF-1 translocation to the
nucleus, thereby confirming abolished HIF-1 upregulation.
Downstream elements of hypoxic injury, such as erythropoie-
tin (EPO), VEGF-A, CTGF, and PDGF protein levels, were
also measured. In response to hypoxic insult, all of these
proteins were induced, and DAPA prevented the induction of
EPO and CTGF and tended to decrease PDGF (P  0.06; see
Fig. 6, F–I).
DISCUSSION
SGLT2i are the newest breakthrough antidiabetics showing
potent renoprotective effects, as recently proven in large clin-
ical prospective trials. The EMPA-REG OUTCOME (52),
CREDENCE (42) and DECLARE-TIMI 58 (55) trials demon-
Fig. 3. Diabetes-induced collagen and fibronectin deposition is ameliorated by dapagliflozin (DAPA). A: representative Sirius red-stained kidney sections of
control, diabetic (D), dapagliflozin (D  DAPA)-, and DAPA  losartan (D  DAPA  LOS)-treated diabetic rats. Original magnification: 200. Scale bar 
100 m. B: representative fibronectin-stained kidney sections of control, D, D  DAPA, and D  DAPA  LOS rats. Original magnification: 400. Scale bar 
50 m. C: percentage of the picrosirius red-positive stained area. D: percentage of the fibronectin-positive stained area. E: renal mRNA expression of fibronectin
1 (Fn1) was normalized to 18S ribosomal RNA (Rn18S) mRNA expression. Bars indicate means  SD, and data were analyzed by one-way ANOVA with a
Holm-Sidak multiple-comparisons test (n  6 in control and diabetic groups and n  7 in treatment groups). **P 
 0.01 vs. the control group; §P 
 0.05 vs.
the diabetic group; §§P 
 0.01 vs. the diabetic group.
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strated improved renal function by SGLT2i in patients with
T2DM; however, this observation has not been confirmed in
T1DM yet, and the molecular background is not fully known.
DKD is traditionally presumed to predominantly affect the
glomeruli, but it is also clearly associated with tubular injury.
More recently, diabetic tubulopathy has emerged as a serious
manifestation of DKD (60). Chronic hyperglycemia elevates
tubular glucose load, and increased exposure and reabsorption
lead to structural and functional changes in the proximal
tubule, which is the focus of our study.
Here, we proved that DAPA treatment minimizes the pro-
gression of renal functional and structural damage in STZ-
induced DKD. Beside improvement in classic renal retention
parameters, DAPA also reduced both urinary and renal KIM-1
and NGAL by 50%, similar to what was recently observed in
a T2DM model (39). Increased urinary and renal levels of
KIM-1 and NGAL are not only highly sensitive indicators of
tubular damage (3, 36) but are also responsible for the devel-
opment of renal inflammation and fibrosis (7, 26).
In the diabetic milieu, connective tissue accumulation leads
to tubulointerstitial fibrosis (25), which is characterized by
dysregulation of ECM remodeling and matrix protein deposi-
tion secreted by activated myofibroblasts. Recently, in a DKD
network model combined with plasma measurements of 44
patients with type 2 diabetes, Heerspink et al. (22) reported that
canagliflozin reverses the molecular processes involved in
diabetes-induced inflammation ECM turnover and fibrosis. By
showing that DAPA has antifibrotic properties both on histo-
logical and molecular levels, we provide experimental evi-
dence that strengthens these clinical observations. We found
that accumulation of myofibroblast marker -smooth muscle
actin and other common fibrosis markers such as collagens and
fibronectin were all alleviated by DAPA treatment. In parallel,
the levels of the classic profibrotic factors Ctgf and Pdgfb were
also reduced, which further supports DAPA’s antifibrotic po-
tential.
At the moment, kidney biopsy is the diagnostic method of
renal fibrosis (9), an invasive process with possible complica-
tions; therefore, research is ongoing to discover other specific
noninvasive (urinary or serum) markers. The formation and
degradation of ECM components leads to specific Protein
Fingerprint peptides as follows: fragments derived from the
collagen propeptides describe active collagen formation,
whereas neo-epitope fragments of collagen mediated by MMP
cleavage reflect collagen degradation. These peptides coming
from the remodeling kidney are released in urine and can be
measured by newly developed immunoassays (13). In our
previous study (30), we showed that the level of the Protein
Fingerprint peptides rPRO-C3 (collagen type III formation),
uC3M (collagen type III degradation), and TUM (collagen type
IV degradation) were increased in the urine of T1DM animals.
Here, we found that DAPA mitigated the increased level of
these markers, reverting the levels of controls. These data and
the positive correlation between urinary markers and tubulo-
interstitial fibrosis confirm the antifibrotic effects of SGLT2i
and encourage the validation and widespread clinical use of
these novel noninvasive biomarkers of fibrotic response.
Because RAASi and SGLT2i have different mechanisms of
action, it is reasonable to apply combination therapy; however,
to our best of knowledge, it has not been previously tested in
T1DM at all, and data in other diseases are also limited. Some
studies suggest that STZ-induced T1DM is more relevant for
investigating DKD because glucotoxicity could be examined
without the frequent comorbidities of T2DM, such as insulin
resistance, obesity, vascular disease, hypertonia, or aging.
Rather surprisingly, in our experiments, DAPA alone was as
effective as the combination therapy, both concerning in vivo
and in vitro experimental outcomes.
Fig. 4. Dapagliflozin (DAPA) reduces diabetes-induced renal protein O-GlcNAcylation. A–D: protein O-linked 	-N-acetylglucosamine addition (O-GlcNAcy-
lation) and levels of O-GlcNAcase transferases (OGT) and O-GlcNAcase (OGA) in control, diabetic, dapagliflozin (DAPA)-, and DAPA  losartan (DAPA 
LOS)-treated diabetic rats. ncOGT, nucleocytoplasmic O-linked N-acetylglucosamine (O-GlcNAc) transferase; sOGT, small O-GlcNAc transferase; OGA-L,
long isoform of OGA. E: representative immunohistochemistry staining of O-linked N-acetylglucosamine (O-GlcNAc) in the kidneys. Original magnification:
400. Scale bar  50 m. Bars indicate means  SD, and data were analyzed by one-way ANOVA with a Holm-Sidak multiple-comparisons test (n  6 in
control and diabetic groups and n  7 in treatment groups). *P 
 0.05 vs. the control group; **P 
 0.01 vs. the control group; §P 
 0.05 vs. the diabetic group;
§§P 
 0.01 vs. the diabetic group.
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There are some results in clinical and experimental T2DM
setups, but, in each case, combination therapy was used when
hypertension was present. Combination of DAPA with RAASi
resulted in lower albuminuria in patients with T2DM; however,
studies were not designed to assess whether the effect of
DAPA on renal variables was independent of glucose or blood
pressure control, and neither proved the synergistic effect of
these two versus other comparators (21). In another study in
patients with uncontrolled hypertension by RAASi, the value
of additional DAPA treatment was assessed on the improve-
ment of blood pressure. This study proved that DAPA reduces
blood pressure and body weight in patients with T2DM with
hypertension and diminishes the need for additional antihyper-
tensive therapy (54). Interestingly enough, addition of DAPA
resulted in a negative result, since no further albuminuria-
lowering effect was detected. In a preclinical model of T2DM,
12 wk of combination therapy of DAPA and irbesartan offered
more improvement in renal retention and histological param-
eters and renal fibrosis than single use of either agent (1). It has
to be emphasized that the aim of that study was to assess
prevention of renal injury instead of addressing the renopro-
tective effect on established renal injury; therefore, therapy
was started from the onset of diabetes and lasted 12 wk. In
Dahl-sensitive hypertensive STZ-treated rats, combination
therapy of luseogliflozin with angiotensin-converting enzyme
inhibitors afforded more reduction of blood pressure, hyperfil-
tration, and some histological injury. Of note, gliflozin therapy
did not have any effect on proteinuria, which argues the
renoprotective efficacy of the treatment (27). Finally, variances
in experimental setups and protocols could explain the diver-
gences in outcomes, and more data and extended investigations
are needed to clarify the possible benefits of combination
therapy.
Various hypotheses exist in the literature regarding how
SGLT2i improve renal function and reduce kidney injury in
T2DM rodent models (28, 34, 48, 50). Hyperglycemia-induced
renal injury is a complex phenomenon in itself, involving
various processes in the proximal tubules among which in-
creased activation of alternative glucose metabolism pathways
and hypoxia have a strong impact and were the focus of our in
vitro investigations.
We have previously shown that, in diabetic rats and in
hyperglycemic proximal tubular cells, protein O-GlcNAcyla-
tion (12) and fibrotic processes were induced (30). Increased
O-GlcNAcylation has been reported to enhance profibrotic
signaling in mesangial cells exposed to high glucose (15, 41).
Fig. 5. Dapagliflozin (DAPA) reduces hyperglycemia-induced protein O-GlcNAcylation in human proximal tubular cells (HK-2 cells). Proximal tubular cells
were incubated with normal glucose (5.5 mM), high mannitol (35 mM), or high glucose (HG; 35 mM) for 24 h. A–D: total protein levels of O-GlcNAcylation,
nucleocytoplasmic O-linked N-acetylglucosamine (O-GlcNAc) transferase (ncOGT), small O-GlcNAc transferase (sOGT), and O-GlcNAcase (OGA-L) of
control, mannitol-, HG-, dapagliflozin (HG  DAPA)-, and DAPA  losartan (HG  DAPA  LOS)-treated HG-treated HK-2 cells. Proteins were normalized
to total protein Ponceau S staining as a loading control. E: representative immunocytochemistry staining and integrated density of O-GlcNAc (green, O-GlcNAc;
blue, nucleus; 20 objective; scale bar  50 m). F–H: mRNA expression of transforming growth factor 	 (TGFB1), platelet-derived growth factor-B (PDGFB),
and connective tissue growth factor (CTGF), which were normalized to GAPDH mRNA expression. Bars indicate means  SD, and data were analyzed by
one-way ANOVA with a Holm-Sidak multiple-comparisons test or Kruskal-Wallis with Dunn comparison test (n  5–6 per group). *P 
 0.05 vs. the control
group; **P 
 0.01 vs. the control group; §P 
 0.05 vs. HG; §§P 
 0.01 vs. HG.
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Because DAPA blocks glucose uptake in proximal tubular cells
(32), we hypothesized that DAPA modifies protein O-Gl-
cNAcylation, thus affecting fibrotic processes. DAPA mini-
mized elevated protein O-GlcNAcylation and reduced OGT
levels in HK-2 cells and in the kidney as well. However, OGA,
which is responsible for removing O-GlcNAc residue, re-
mained unchanged, suggesting that DAPA inhibits the addition
of O-GlcNAc rather than facilitates its removal. In parallel,
whereas all profibrotic growth factors were upregulated under
hyperglycemic conditions, only CTGF was reduced by DAPA.
Surprisingly, TGFB1 and PDGFB were not affected.
Tubular hypoxia is a major driver of DKD progression (46).
As early as 1994, Körner et al. (29) reported that the O2
consumption of proximal tubules isolated from STZ-treated
diabetic rats is greater than that of control animals. These
findings have been confirmed by various models and methods
throughout the years. Palm et al. (40) reported that renal tissue
O2 tension is decreased in diabetic rats using Clark-type
microelectrodes. Later, enhanced tubular O2 consumption was
further verified by MRI imaging (6). Glomerular hyperfiltra-
tion and elevation of glucose reabsorption through SGLTs
enhances Na-K-ATPase activity, resulting in increased O2
consumption in diabetes (16). HIF-1 activation is one of the
most critical factors that triggers hypoxia adaptation. During
hypoxia, HIF-1 stabilizes and translocates to the nucleus,
where it dimerizes with HIF-1	, and HIF transcriptional ac-
Fig. 6. Dapagliflozin (DAPA) treatment minimizes tubular hypoxia. A: hypoxia-inducible factor-1 (HIF-1) immunocytochemistry (green, HIF-1; blue,
nucleus; 20 objective; scale bar  50 m). B–I: HIF1A mRNA expression (B), HIF-1 protein level (C), HIF-1 integrated density (D), HIF-1
nucleus-to-cytosol ratio (E), and protein levels of erythropoietin (EPO; F), VEGF-A (G), connective tissue growth factor (CTGF; H), and platelet-derived growth
factor (PDGF; I) in human proximal tubular cells (HK-2 cells). HIF1A was normalized to 18S ribosomal RNA (RN18S) mRNA expression. Proteins were
normalized to total protein Ponceau S staining as a loading control. Proximal tubular cells were treated with DAPA or DAPA  losartan (LOS) for 22 h before
2 h hypoxia (1% O2). Bars indicate means  SD, and data were analyzed by one-way ANOVA with a Holm-Sidak multiple-comparisons test or Kruskal-Wallis
with Dunn comparison test (n  5–6 per group). *P 
 0.05 vs. the control group; **P 
 0.01 vs. the control group; §P 
 0.05 vs. hypoxia; §§P 
 0.01 vs.
hypoxia.
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tivity is remarkably enhanced (45). To investigate whether
DAPA is protective via reduction of tubular hypoxia indepen-
dent of its antihyperglycemic effect, an in vitro low-grade
hypoxia model was applied. As a general hypoxic response,
HIF-1 is activated under 1% O2 concentration in a large
variety of cell types (e.g., mouse Ltk fibroblasts, Chinese
hamster ovary cells, rat fibroblasts, human Hep3B hepatoblas-
toma cells, or human embryonic kidney cells; see Ref. 51).
HIF-1 has also been reported to be elevated in 1% O2 milieu,
specifically in proximal tubular cells (10, 31, 58). In line with
the literature, we found that hypoxia led to a robust HIF-1
increment and translocation to the nucleus of proximal tubular
cells. DAPA reduced protein levels and mitigated the HIF-1
nucleus-to-cytoplasm ratio, suggesting its effect on hypoxic
pathway activity. To confirm this phenomenon, downstream
elements of the general HIF pathway were investigated, e.g.,
O2-sensing EPO production and VEGF-mediated angiogene-
sis. Both EPO and VEGF-A protein levels increased because of
hypoxia. DAPA mitigated the level of EPO, whereas the VEGF
pathway was not affected. Based on our results, one can
hypothesize that DAPA moderates tubular hypoxia as shown
by reduced HIF-1 activity and EPO production.
It is a well-known fact that chronic hypoxia leads to tubu-
lointerstitial fibrosis via HIF-1-regulated ECM production
(17, 24). In various cell types, hypoxia increases CTGF (23)
and PDGFB expression (57) in a HIF-1-dependent way. Here,
we showed that DAPA decreases hypoxia-induced CTGF and
PDGF production, suggesting that its antifibrotic effects might
be in direct connection with diminished hypoxia. A detailed
clarification of the effect of SGLT2i on hypoxia-induced com-
plex molecular pathways was beyond the main scope of this
study; however, our observations might open a new potential
for SGLT2i in hypoxia-associated kidney damage, which
should be further examined.
Our results are the first experimental evidence for the anti-
fibrotic effect of DAPA under hyperglycemic and hypoxic
conditions that occur simultaneously in the diabetic kidney.
These findings provide novel data supporting the link between
glucose toxicity, tubular hypoxia, and fibrosis, a vicious trio
that seems to be targeted by DAPA. All of these mechanisms
are important parts in the puzzle of the complex system behind
the organoprotective effect of SGLT2i.
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